MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy AL Kasinski, FJ Slack Nature Reviews Cancer 11 (12), 849-864, 2011 | 1090 | 2011 |
Aberrant regulation and function of microRNAs in cancer BD Adams, AL Kasinski, FJ Slack Current Biology 24 (16), R762-R776, 2014 | 520 | 2014 |
Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation EA Orellana, AL Kasinski Bio-protocol 6 (21), e1984-e1984, 2016 | 407 | 2016 |
miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma AL Kasinski, FJ Slack Cancer research 72 (21), 5576-5587, 2012 | 297 | 2012 |
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao, E Shimer, S Dysart, ... Oncogene 34 (27), 3547-3555, 2015 | 237 | 2015 |
Inhibition of IκB kinase-nuclear factor-κB signaling pathway by 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin AL Kasinski, Y Du, SL Thomas, J Zhao, SY Sun, FR Khuri, CY Wang, ... Molecular pharmacology 74 (3), 654-661, 2008 | 185 | 2008 |
MicroRNAs in cancer: a historical perspective on the path from discovery to therapy EA Orellana, AL Kasinski Cancers 7 (3), 1388-1405, 2015 | 149 | 2015 |
MicroRNA-223 suppresses the canonical NF-κB pathway in basal keratinocytes to dampen neutrophilic inflammation W Zhou, AS Pal, AYH Hsu, T Gurol, X Zhu, SE Wirbisky-Hershberger, ... Cell reports 22 (7), 1810-1823, 2018 | 105 | 2018 |
MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic W Li, Y Wang, R Liu, AL Kasinski, H Shen, FJ Slack, DG Tang Frontiers in cell and developmental biology 9, 640587, 2021 | 104 | 2021 |
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer EA Orellana, S Tenneti, L Rangasamy, LT Lyle, PS Low, AL Kasinski Science translational medicine 9 (401), eaam9327, 2017 | 88 | 2017 |
Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression MM Nellis, A Kasinski, M Carlson, R Allen, AM Schaefer, EM Schwartz, ... Molecular genetics and metabolism 80 (1-2), 189-195, 2003 | 76 | 2003 |
MicroRNA therapeutics in preclinical cancer models M Kim, AL Kasinski, FJ Slack The lancet oncology 12 (4), 319-321, 2011 | 73 | 2011 |
Animal models to study microRNA function AS Pal, AL Kasinski Advances in cancer research 135, 53-118, 2017 | 64 | 2017 |
Potential microRNA therapies targeting Ras, NFκB and p53 signaling ALKFJ Slack Current opinion in molecular therapeutics 12 (2), 147-157, 2010 | 54 | 2010 |
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma M Gilbert-Ross, J Konen, J Koo, J Shupe, BS Robinson, WG Wiles IV, ... JCI insight 2 (5), 2017 | 42 | 2017 |
Insulin increases branched-chain α-ketoacid dehydrogenase kinase expression in Clone 9 rat cells MM Nellis, CB Doering, A Kasinski, DJ Danner American Journal of Physiology-Endocrinology and Metabolism 283 (4), E853-E860, 2002 | 36 | 2002 |
Integration of apoptosis signal-regulating kinase 1-mediated stress signaling with the Akt/protein kinase B-IκB kinase cascade MC Puckett, EH Goldman, LM Cockrell, B Huang, AL Kasinski, Y Du, ... Molecular and cellular biology 33 (11), 2252-2259, 2013 | 33 | 2013 |
Enhancing microRNA activity through increased endosomal release mediated by nigericin EA Orellana, AM Abdelaal, L Rangasamy, S Tenneti, S Myoung, PS Low, ... Molecular Therapy-Nucleic Acids 16, 505-518, 2019 | 30 | 2019 |
New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange L Rangasamy, V Chelvam, AK Kanduluru, M Srinivasarao, NA Bandara, ... Bioconjugate chemistry 29 (4), 1047-1059, 2018 | 28 | 2018 |
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer AS Pal, M Bains, A Agredo, AL Kasinski Biochemical pharmacology 189, 114154, 2021 | 25 | 2021 |